A Bipartisan Senate Investigation Just Confirmed What 28 Million Americans Suspected: The Hearing Aid Industry Has Been Running a Coordinated Scam — And a $99 Device Is the Fix They Spent $1.2 Million Trying to Block

In 2021, Senators Elizabeth Warren and Chuck Grassley — political opposites who agree on very little — released the findings of a joint investigation into the hearing aid industry.

What they found wasn't a gray area.

When the FDA proposed allowing over-the-counter hearing aids to be sold without a prescription, the five companies that control more than 90% of the global hearing aid market organized a response. They generated thousands of public comments opposing the rule change. Regulators received so many letters that it appeared the public was overwhelmingly against affordable hearing access.

There was one problem. The senators' investigation found that "the wording in large passages from these letters is identical — including typos."

The letters were fake. Written by industry operatives. Submitted under the names of real people who had no idea their identities were being used.

The hearing aid industry ran a coordinated astroturf campaign to prevent you from buying an affordable hearing aid. They spent $1.2 million lobbying Congress against the rule. They weren't trying to protect public health. They were protecting $7,000 price tags.

That's documented fact. Confirmed by a bipartisan Senate investigation.

And here's the part that matters for the 28 million Americans who need hearing aids but can't afford them: the campaign failed. Over-the-counter hearing aids became legal in October 2022. The Big Five's stock prices dropped immediately when the announcement was made.

A $99 hearing aid now exists that does something they spent years and millions of dollars trying to prevent.

To understand what you're actually paying for at an audiologist's office — and what you're not — you need to understand how the hearing aid market was structured for the past 30 years.

Five companies — Starkey, Sonova, WS Audiology, William Demant, and GN Store Nord — have controlled more than 90% of the global hearing aid market since the 1990s. They don't sell to consumers directly. They sell through audiologists, who are trained, in many cases financially incentivized, to sell their products.

Here's what that model produces.

A hearing aid that costs roughly $100–$200 to manufacture gets wrapped in audiologist fitting appointments, office overhead, distribution margins, brand markup, and regulatory compliance costs. By the time it reaches the patient, it carries a $4,672 average price tag. Medicare covers none of it. Most insurance covers, at best, 15%.

The result: only 16% of Americans aged 20–69 who need hearing aids are using them.

The other 84% are doing what you've been doing. Nodding. Faking it. Turning the TV up loud enough that their spouse moves to another room. Slowly stopping going to the places where hearing matters — restaurants, church, family gatherings — because the cognitive effort of following a conversation they can't hear has become more exhausting than staying home.

Before we get to the device itself, there's something the industry has preferred to keep quiet — because it would have accelerated the regulatory pressure for affordable alternatives decades sooner.

Untreated hearing loss is not a neutral inconvenience.

Research from the National Institutes of Health and the Johns Hopkins Bloomberg School of Public Health established clearly that mild hearing loss doubles dementia risk. Moderate hearing loss triples it. Severe hearing loss increases it fivefold.

The ACHIEVE study — the largest clinical trial ever conducted on hearing loss intervention in adults — followed participants over three years and found that treating hearing loss reduced cognitive decline by 48% in adults at high risk.

Here is what you are actually paying for inside a prescription hearing aid.

Your inner ear contains thousands of microscopic hair cells called stereocilia. Different groups detect different frequencies of sound. Some pick up bass frequencies: engines, thunder, low instruments. Others pick up high frequencies: alarms, birds, upper musical registers.

But the cells that detect human speech — tuned to the 1,000–4,000 Hz frequency range where voices, consonants, and conversational nuance live — are the most heavily used cells in your auditory system. They are, consequently, the first to wear out with age. And unlike many cells in the body, they do not regenerate.

This is why the experience of age-related hearing loss is not silence. It is confusion. You hear sound. You cannot make out speech. You can hear the television is on, but the dialogue doesn't register. You can hear your spouse is talking but the words don't resolve clearly. The cells that detect everything else are fine. The cells tuned to human voices have eroded.

Cheap hearing amplifiers do not address this problem. An amplifier applies uniform volume increase to all incoming sound. It makes the voice you're trying to hear louder — and simultaneously makes the restaurant noise, the background music, the air conditioning, and every other competing sound equally louder. The result is more noise, same confusion.

What distinguishes a prescription hearing aid from a cheap amplifier is a single component: a digital signal processing chip that can identify the speech frequency range and amplify only those frequencies, while actively suppressing sound outside them.

That chip is what you're paying for. Everything else is overhead.

The Nebroo Pro 3.0 contains that chip — called the Vox Humana, Latin for "human voice" — in a completely-in-canal device that retails for $99.

The result is not a louder world. It is a clearer one.

In practical terms: at a restaurant, a standard amplifier floods your brain with the full noise environment at increased volume. The Vox Humana chip filters that environment, identifies the speech signal from the person across from you, and delivers that signal with clarity while reducing the ambient noise around it.

This is the same fundamental technology inside prescription hearing aids that cost $4,672. Delivered in a device that costs $99 because it arrives direct-to-consumer, with no audiologist overhead, no office lease, no fitting appointments, and no brand distribution margin.

The Nebroo is a completely-in-canal (CIC) hearing aid. It sits inside the ear canal with nothing visible from outside. No tubes. No wires. No beige hook behind the ear. No indication to the outside world that you are wearing anything at all.

It comes with 10 silicone ear dome sizes so users can find a comfortable, secure fit — the same fitting approach used in audiologist offices, without the appointment.

Battery life: 19 hours per charge. The charging case holds three additional full charges — 76 hours of use before requiring a wall outlet.

Setup: none. No audiologist visit. No hearing test. No app to download. No Bluetooth pairing. No firmware updates. Take it out of the box, choose the dome that fits, place it in the ear canal, turn it on. Clear speech is audible within seconds.

120-day money-back guarantee. One-year warranty. HSA/FSA eligible. Free shipping.

For context: $99 is less than one audiologist consultation. It is less than the average American spends trying cheap Amazon amplifiers before finding a solution that actually works. It is less than two months of the hearing supplements that do nothing.

It comes with a 120-day money-back guarantee — four full months to test it in every real-world situation that matters. At the restaurant. At church. On the phone. At the family dinner table. If it doesn't deliver, it goes back, and every dollar is refunded.

Use the product the hearing aid industry spent $1.2 million trying to prevent. The one a bipartisan Senate investigation confirmed they didn't want you to have access to. For $99, with 120 days to decide if it works.

The wall they built around affordable hearing access has come down. The only question is whether you're going to walk through it.